NDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ARAMINE (metaraminol bitartrate) is an injectable sympathomimetic amine approved in 1954 for treating hypotension and shock states. It acts as an alpha- and beta-adrenergic agonist to restore blood pressure through vasoconstriction and increased cardiac output. This is a legacy acute-care therapeutic with limited modern clinical development.
LOE Approaching
LOE-stage product with minimal linked career opportunities; small team likely focused on regulatory maintenance rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ARAMINE positions represent niche, stable roles focused on regulatory maintenance, compliance, and supply continuity rather than commercial growth or R&D innovation. Career trajectories on this product typically involve transition to higher-growth assets or internal mobility to strategic functions.
Regulatory Affairs SpecialistMedical Information Specialist
Worked on ARAMINE at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.